A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether patients with chronic kidney disease who required dialysis that undergo valve surgery have better surgical recovery rates with bioprostheses than with mechanical valves. Altogether more than 96 papers were found using the reported search, of which 12 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. Patients with end stage renal disease (ESRD) undergoing cardiac surgery are very fragile, with high in-hospital mortality rates (13-36%) and limited life expectancy (15-42 months in selected studies). Two studies outlined that diabetic ESRD, neurological impairment, age at the operation and poor ventricular function are the strongest predictors of early and late morbidity and mortality. Based on American Heart Association/American College of Cardiology (AHA/ACC) 1998 valvular guidelines, bioprostheses were considered a contraindication in dialysis patients; this statement derived from anecdotal reports of accelerated valve degeneration. Structural valve deterioration was reported in only 5 of 1347 patients who received bioprosthesis through the studies and independent from implantation site. Likelihood of degeneration is low, with a calculated valve-excision rate of 7%, and occurred in a broad range of time (from 10 to 156 months). The AHA/ ACC 2006 valvular revised guidelines removed the previous statement (1998) of class IIa recommendation for mechanical valves and class III for tissue valves; in the focus update of 2008, there is still no specific indication for valve selection in dialysis patients, but difficulties in maintaining anticoagulation in these patients was noted. Stroke, haemorrhage and gastro-intestinal bleeding events occurred in almost 15% of patients with mechanical valves during the follow-up, while bioprostheses showed an average event rate of 3.9%. All but one of the selected studies reported no differences in survival between mechanical and biological valves; in five of seven studies, the patients who received bioprostheses were older (mechanical vs biological average 53 years vs 61.4 years), in one study, patients had undergone dialysis for longer period of time, and, in another study, they had suffered from more previous myocardial infarction (mechanical vs biological 9.1% vs 36.2%). Therefore, survivals have been biased in favour of mechanical valves. Taking together these data, biological valves are a suitable treatment for dialysis-dependent patients and, while not superior to mechanical valves in survival due to the aforementioned study biases, exhibit lower valverelated and anti-coagulation related events.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in the ICVTS [1] . 
THREE-PART QUESTION

CLINICAL SCENARIO
A 56-year old male patient who has been on dialysis for 5 years requires an aortic valve replacement (AVR) for stenosis. The usual balance of which valve to use does not seem to apply to him, as he has a more limited survival expectancy, and anticoagulation complication might be more important to him, but, at Bio n = 0 vs mech n = 7 (P = 0.002)
Bio n = 0 vs mech n = 10 (P = 0.001) 29 ± 23 (bio) vs 33 ± 17 (mech) days (P = NS) n = 1 (bio) vs n = 2 (mech) (P = NS)
Retrospective study There is a little need for a prosthetic valve that will endure more than a few years Early (within 30 days) Group 1: 36% n = 17
Continued
Retrospective study with broad range of time (27 years)
Small number of patients Group differ for age 
SEARCH OUTCOME
Ninety-six articles were found using the reported search. From these, 12 papers were identified that provided the best evidence to answer the question. These are presented in Table 1 .
RESULTS
In the American Heart Association/American College of Cardiology (AHA/ACC) 1998 valvular guidelines [2] , bioprosthetic valves were considered as a class III indication. This statement was based on previous anecdotal reports of dialysis-related accelerated calcification of this type of valve [4, 5] . One year before the release of the aforementioned guidelines, Lucke et al. [6] found no differences in terms of mortality between bioprostheses and mechanical valves, the latter having a higher incidence of anticoagulation-related events; bioprostheses showed no degeneration that required reoperation at 32 months of follow-up.
Kaplon et al. [7] found that calcification is unlikely to occur over 5 years of follow-up; as patients had a limited life expectancy, they concluded that there is a little need of a valve that will endure more than few years.
Brinkman et al. [8] outlined that, despite no differences in the early period, in the long term, the mechanical valve group experiences a higher rate of cerebro-vascular events (CVE) (biological vs mechanical valves: 8.3% vs 17.6%; P = NS) and bleeding (biological vs mechanical valves: 8.3% vs 38.3%; P = 0.07). Of note, they also found only two cases of tissue valve degeneration over the follow-up period with an expected valve excision rate of 7%.
Herzog et al. [9] found that age (>75 years) and diabetic end stage renal disease (ESRD) were the strongest predictors of death; liver disease, double valve replacement and associated CABG also negatively affected the outcome, as well as mitral valve replacement (MVR) over AVR.
A survival advantage of ESRD patients in favour of mechanical valves was found by Chan et al. [10] in valve replacement as sole procedure (biological vs mechanical valves: 19.1 ± 10.4% vs 53.6 ± 15.4%; P = 0.0254) with comparable freedom from adverse events, but not when CABG is associated (24.4 ± 9.1% vs 50.0 ± 20.4% P = 0.7515); these results are also tempered by the different age between the two groups, as the patients who received biological valves were older [hazard ratio (HR) 1.04, P = 0.04], suffered from previous myocardial infarction (HR 1.5) and had more revascularization procedures (HR 1.4).
In contrast, Toole et al. [11] found a lower freedom from adverse events in the mechanical valve group, namely thromboembolism (mechanical vs tissue valves: 75 ± 15% vs 100% P = 0.01), haemorrhage (44 ± 17% vs 97 ± 3% P = 0.002), valve-related morbidity and mortality (37 ± 14% vs 69 ± 9% P = 0.037), although overall mortality at 4 years after the procedure was comparable with the tissue valve group (65% vs 42%; P = 0.15).
Filsoufi et al. [12] analysed the outcome after valve replacement in dialysis-independent (group 1) and dialysis-dependent (group 2) patients with ESRD; the authors found no significant differences at 5 years regarding mortality (group 1 vs group 2: 39% vs 37%; P = NS), overall life expectancy (53.1 ± 10.1 vs 49.1 ± 7.1%; P = NS) and valve-related survival (55 ± 8.4% vs 42.4 ± 11.8; P = 0.44).
Patient's preoperative status impact on outcome was analysed by Boeken et al. [13] , where obesity [odds ratio (OR) 2.2; P = 0.001], neurological impairment (OR 2.2; P = 0.001), reoperation for bleeding (OR 2.8; P = 0.001) and poor ventricular function (OR 2.1; P = 0.001) were associated with negative prognosis. Complications were higher in the mechanical valve group (overall: 21.2% vs 15.3; P < 0.05), with more CVE (18.2% vs 8.3%; P < 0.05), bleeding (15.9% vs 11.7%; P < 0.05) and longer hospital stay (19.5 ± 5.4 days vs 15.6 ± 4.1 days; P < 0.05).
In their article, Thourani et al. [14] confirmed that the prognosis is dictated in the long term more by the chronic ESRD rather than the type of prosthesis, with no significant difference between biological and mechanical valves (P = NS), regardless of implant position (aortic vs mitral, P = NS); Umezu et al. [15] in their Japanese population study outlined a better survival of patients due to a lower prevalence of diabetic nephropathy (glomerulonephritis 75% vs diabetes 25%), which was unaffected by the prosthesis choice; Tanaka et al. [16] reported higher survival for AVR in dialysis patients consistent with the findings of Lucke [6] and Herzog [9] (55.7 ± 7.6% vs 42 ± 14% vs 14.8 ± 1.3%, respectively); bioprostheses had lower complications (P < 0.001 mechanical vs biological), while the long-term outcome is tempered by the older age of this group.
Böning et al. [17] found that the rate of events seems higher in the non-dialysis group (dialysis vs non-dialysis-biological valves: mortality 0% vs 2.3%; stroke 0% vs 6.4%; bleeding 0% vs 4.2%-mechanical valves: mortality 0% vs 2.4%; stroke 3.1% vs 7.0%; bleeding 0% vs 6.7%). An explanation of this phenomenon is that patients in dialysis usually do not outlive their prosthesis lifespan, while chronic kidney disease (CKD) patients have a long enough life expectancy to experience valve-related events.
CLINICAL BOTTOM LINE
Bioprostheses have been shown to be comparable to mechanical valves in that they bear significantly fewer valve-related and anticoagulation-related events that typically effect morbidity and mortality. Surgeons must keep in mind that valve choice is not the only factor effecting patients' survival. As the majority do not outlive the predicted lifespan of the valve itself so that accelerated degeneration is unlikely to occur, bioprostheses seems to be a plausible choice in this patient's population.
